Kimberly-Clark to Acquire Kenvue for $48.7 Billion in Landmark Consumer Health Deal

Nov 04, 2025 19:53 CST Updated 19:53

Johnson & Johnson

Medical Device R&D and Manufacturer

Free attendance, scan to registerOne

On November 3, a cross-border giantKimberly-ClarkAndKefu(Kenvue, formerly known as Johnson & Johnson Consumer Health) jointly announced that they have reached a final agreement:Kimberly-ClarkIn cash and stock, for approximately487Billion US dollarsEnterprise Value Fully Acquires Kefu.

After the M&A news came out,KefuStock Price on MondaySurged 12.32%, reported at $16.14, total market value$30.92 billion，But the year-to-date decline is still 22%.

The two companies said that the merged company will bring together 10 brands with annual sales reaching one billion dollars, and the annual revenue will reach$32 billion. In a statement, the two companies said that the products produced by the new company "will benefit nearly half of the world's population, covering all stages of life," including Johnson & Johnson (Johnson’s) Baby products, Clean & Clear (Clean & Clear) Skin care products, Kleenex (Kleenex) Tissue, Listerine (Listerine) Mouthwash and Deban (Depends) Adult Diapers.

KefuIn2022FromJohnson & JohnsonSpun off, Johnson & Johnson retained its well-known name for its larger pharmaceuticals division and divested its consumer brands. This move was widely anticipated.KefuWill become an acquisition target.

The transaction is expected to be completed byCompleted in the second half of next yearUpon completion of the transaction, Kimberly-Clark's shareholders will own approximately54%The shares, the remaining shares are held byKefuHeld by the company's shareholders.

However,This deal carries considerable risks.。

Monday,KefuAnnounce Total Sales for the Quarter Ended September 28Decreased by 4.4%, including the self-care division with Tylenol, also saw salesDecreased by 5.3%。

The company explained that the decline in sales was due to "reduced trade inventory among certain customers," likely because cash-strapped clients turned to purchasing similar quality but lower-priced private-label products—this could be a warning signal for the new company betting on a range of well-known brands.

KefuThe company may face severe legal scrutiny due to charges from the Trump administration. Last week, Texas Attorney General Ken Paxton accusedKefuThe company filed a lawsuit, claiming that the company "deceptively" marketed Tylenol to pregnant women and stated that the drug is associated with an increased risk of autism.KefuThe company said it would "vigorously defend" itself against the charges.

Mike Hsu, CEO of Kimberly-ClarkOn Monday, during a conference call with analysts regarding the Tylenol issue, it was stated that "the board carefully considered all risks and opportunities" and held multiple meetings with "medical, regulatory, and legal experts," ultimately deciding that the deal represented "an opportunity to create generational value for both companies."

Kirk Perry, CEO of KenvueAdded: "We firmly support the science and safety of our products. These aspects have been researched for decades, and we, like the medical community, always adhere to these scientific bases."

Kimberly-Clark AcquisitionKefuIt will become the fourth largest consumer goods transaction globally, only behind Altria Group's $111 billion spin-off of Philip Morris International in 2008, British American Tobacco's $64 billion acquisition of Reynolds American in 2015, and Procter & Gamble's $61 billion acquisition of Gillette in 2005.

·END·

Previous ·Selected